Compare Aurora Cannabis Inc (ACB) vs MasTec Inc (MTZ) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

MTZ trades at $380.63, up 1.93% today, with a neutral technical signal. The stock shows strong fundamental momentum, beating earnings estimates in three consecutive quarters, and holds a record $20.3 billion backlog. Recent news highlights a $1.65 billion acquisition of Superior Group to expand data center infrastructure capabilities, positioning the company for growth in AI-driven demand.

Outlook remains positive with 89% analyst buy ratings and a $476.62 consensus price target, implying 25% upside. Key risks include integration challenges from acquisitions and execution risks on large projects. Revenue growth is supported by infrastructure spending trends, but valuation multiples are elevated relative to industry peers.